Retrospective Comparison of Chemotherapy Plus Anti-HER2 Therapies at First-line Treatment in Patients with Metastatic Gastric Adenocarcinoma

Yıl 2022, Cilt: 49 Sayı: 3, 468 - 476, 02.09.2022

Fatih Gurler Aysegul İlhan Gulesen Berna Oksuzoglu

https://doi.org/10.5798/dicletip.1170175

Öz

Aim: We aimed to compare the efficacy and the safety of cisplatin plus 5-FU plus trastuzumab and mFOLFOX-6 plus trastuzumab at first-line treatment in HER2-positive metastatic gastric cancer.
Method: It was a retrospective observational monocentric study. Patients diagnosed with HER2-positive metastatic gastric adenocarcinoma between January 2013 and December 2020 in Dr AY Ankara Oncology TRH were screened. Patients treated at least one cycle of treatment with either CF-T or mFOLFOX-T were included. Survival outcomes and treatment compliance of patients were compared between groups.
Results: Of 52 patients, 55.8% (n=29) of patients were treated with CF-T, and 44.2% (n=23) with mFOLFOX-T. The median age at diagnosis was 60 years (IQR: 52-70) in the CF-T and 64 years (IQR: 59-70) in the mFOLFOX-T groups. De novo metastatic disease comprised 96.6% (n=28) of patients in the CF-T and 69.6% (n=16) in the mFOLFOX-T groups (p=0.016). Both IHC3+ and ISH positivity were observed 82.8% (n=24) of patients in the CF-T and 56.5% (n=13) in mFOLFOX-T groups (p=0.038). The mPFS was 10.4 months (95% CI 8.7-12.2) in the CF-T and 6.5 months (95% CI 5.5-7.6) in the mFOLFOX-T groups (p=0.532). The mOS was 12.2 months (95% CI 11.3-13.2) in the CF-T and 12.5 months (95% CI 9.8-15.5) in the mFOLFOX-T groups (p=0.974). No statistically significant difference regarding at least one dose reduction (31.0% vs 21.7%, p=0.453) and at least one dose delay (24.1% vs 21.7%, p=0.838) was observed between groups.
Conclusion: It was revealed that CF-T and mFOLFOX6-T had similar efficacy and tolerability in patients with HER2-positive metastatic gastric adenocarcinoma.

Anahtar Kelimeler

metastatic gastric cancer, anti-HER2, FOLFOX, CF, FOLFOX, CF

Kaynakça

• 1.Sung H, Ferlay J, Siegel RL, et al. Global cancerstatistics 2020: GLOBOCAN estimates of incidenceand mortality worldwide for 36 cancers in 185countries. CA Cancer J Clin. 2021;71:209-49.
• 2.Bass AJ, Thorsson V, Shmulevich I, et al.Comprehensive molecular characterization ofgastric adenocarcinoma. Nature. 2014;513:202.
• 3.Van Cutsem E, Bang Y-J, Feng-Yi F, et al. HER2screening data from ToGA: targeting HER2 in gastricand gastroesophageal junction cancer. Gastriccancer. 2015;18:476-84.
• 4.NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines®) Gastric Cancer Version 2.2022— January 11, 2022 (https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf).
• 5.Bang Y-J, Van Cutsem E, Feyereislova A, et al.Trastuzumab in combination with chemotherapyversus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophagealjunction cancer (ToGA): a phase 3, open-label,randomised controlled trial. Lancet. 2010;376:687-97.